Key Points
- Michael Benkowitz, United Therapeutics' COO, sold 22,500 shares on February 2 at an average price of $470.95 for a total of $10,596,375, as disclosed in an SEC filing.
- He has executed a string of insider sales since December, totaling roughly $98 million across multiple transactions, signaling substantial offloading of stock by the COO.
- United Therapeutics trades around $478 with a market cap of about $20.6 billion, and analysts carry a consensus rating of Moderate Buy with an average price target near $509.50.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Jan Malcolm sold 50 shares of United Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $474.23, for a total transaction of $23,711.50. Following the completion of the sale, the director owned 270 shares in the company, valued at $128,042.10. This trade represents a 15.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jan Malcolm also recently made the following trade(s):
- On Friday, January 16th, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $460.98, for a total transaction of $23,049.00.
- On Monday, January 5th, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $495.01, for a total transaction of $24,750.50.
- On Tuesday, December 23rd, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $512.12, for a total transaction of $25,606.00.
- On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $482.98, for a total value of $24,149.00.
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $478.27 on Wednesday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The company has a market cap of $20.59 billion, a P/E ratio of 18.12, a P/E/G ratio of 2.53 and a beta of 0.85. The stock's 50-day simple moving average is $487.07 and its 200 day simple moving average is $424.45.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. HC Wainwright increased their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a "buy" rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research note on Thursday, October 30th. Weiss Ratings restated a "buy (b)" rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Wells Fargo & Company upped their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the company an "equal weight" rating in a report on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $509.50.
Check Out Our Latest Analysis on UTHR
Institutional Trading of United Therapeutics
A number of hedge funds have recently modified their holdings of the stock. Clearstead Advisors LLC grew its stake in United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock valued at $117,000 after buying an additional 23 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock worth $472,000 after acquiring an additional 28 shares during the period. Archer Investment Corp grew its position in shares of United Therapeutics by 9.5% in the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company's stock valued at $149,000 after purchasing an additional 31 shares during the last quarter. F m Investments LLC grew its position in shares of United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company's stock valued at $741,000 after purchasing an additional 33 shares during the last quarter. Finally, HB Wealth Management LLC increased its stake in shares of United Therapeutics by 2.9% during the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock worth $355,000 after purchasing an additional 35 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
